Ar­bu­tus re­gains rights to he­pati­tis B as­set in Chi­na; Forte’s $75M of­fer­ing

2 weeks ago
News Briefing

Bright­Gene seeks a part­ner for Zep­bound-beat­ing obe­si­ty shot

2 weeks ago
R&D

Bay­er's stem cell group Blue­Rock re­struc­tures pipeline, lays off staffers

2 weeks ago
People
Cell/Gene Tx

Bio­gen un­veils first da­ta from Spin­raza fol­low-on, plans late-stage pro­gram

2 weeks ago
R&D

FDA in­ves­ti­gat­ing Sarep­ta’s Duchenne gene ther­a­py fol­low­ing pa­tient deaths

2 weeks ago
Cell/Gene Tx
FDA+

RFK Jr. pledges to keep the US at the cen­ter of the biotech 'rev­o­lu­tion'

3 weeks ago
Pharma

For­mer FDA sci­en­tist and psy­che­delics re­searcher hired as CDER deputy di­rec­tor

3 weeks ago
People
FDA+

RFK Jr. says he did not com­mit to up­hold­ing ACIP ros­ter to se­cure Cas­sidy’s back­ing

3 weeks ago
Pharma
FDA+

No­vo and Him­s' crossed wires

3 weeks ago
Health Tech

Ex­clu­sive: Mikael Dol­sten joins gene edit­ing star­tup's board and eyes 'op­por­tu­ni­ties' with new FDA lead­ers

3 weeks ago
People
Startups

Ex­clu­sive: FDA's Makary sought re­jec­tion of KalVista’s drug in an un­usu­al move by com­mis­sion­er, sources say

3 weeks ago
FDA+

Rev­o­lu­tion inks up to $2B 'flex­i­ble' fund­ing deal to ad­vance RAS in­hibitor pipeline

3 weeks ago
Financing
Deals

Nek­tar's mid-stage eczema da­ta de­liv­er key win in bid for com­pa­ny turn­around

3 weeks ago
R&D

Ar­riVent plots next steps for lung can­cer drug; Neu­ron23's $96.5M raise

3 weeks ago
News Briefing

UK gov­ern­ment blue­prints am­bi­tion to be a key life sci­ences hub 

3 weeks ago
R&D
Pharma

Nu­va­lent clos­es in on FDA fil­ing for lung can­cer drug with topline Phase 1/2 da­ta

3 weeks ago
R&D

The pol­i­tics of vac­ci­na­tion take cen­ter stage as RFK Jr.’s re­built CDC pan­el is set to meet

3 weeks ago
FDA+

Up­dat­ed: Am­gen plans low­er, slow­er Mar­i­Tide dos­es for obe­si­ty drug’s Phase 3

3 weeks ago
R&D

As­traZeneca, Dai­ichi Sankyo gain lung can­cer in­di­ca­tion for En­her­tu suc­ces­sor

3 weeks ago
Pharma
FDA+

Roche plans to pit next-gen he­mo­phil­ia A an­ti­body against Hem­li­bra in Phase 3

3 weeks ago
R&D

Supreme Court asks DOJ to weigh in on Hik­ma ‘skin­ny la­bel’ fight against Amarin

3 weeks ago
Pharma
Law

Ex­elix­is' pos­i­tive Phase 3 col­orec­tal can­cer da­ta boost stock

3 weeks ago
R&D

No­vo ends short-lived part­ner­ship with Hims over com­pound­ed obe­si­ty drugs

3 weeks ago
Startups
Pharma

For­ma­tion Bio’s up to €545M li­cens­ing deal with Sanofi; Ot­su­ka, Har­bour Bio­Med team up

3 weeks ago
News Briefing
First page Previous page 3456789 Next page Last page
A service from the Financial Times